Huya Bioscience to collaborate with Tianjin Institute on global development project from China

Huya Bioscience International, a global biopharma company specializing in biopharma opportunities originating in China, is to launch a joint venture with Tianjin Institute of Pharmaceutical Research (TIPR) to develop medical technologies and therapies for global markets.

The collaboration will be known as TIPR-HUYA-AIM and will combine Huya’s global development experience with TIPR’s prestigious credentials and commercial success in China. The two bodies will identify and evaluate medical opportunities in and outside China, and will use TIPR’s infrastructure and Huya’s global network to accelerate product development.

Huya focuses on increasing the speed of development and value creation for Chinese-sourced biopharma innovation in worldwide markets. This is the latest of its collaborations with research institutions across China, and is jointly headquartered in Shanghai and San Diego. TIPR was originally established by the State Food and Drug Administration in 1959 and is now wholly state-owned.